Website www.aurobindo.com Founded 1986 Number of employees 11,500 | Industry Pharmaceuticals Revenue 121.2 billion INR (2015) | |
 | ||
Key people P.V.Ramprasad Reddy, , Mr. K. Nityananda Reddy, Mr. Govind, Dr. A Rama Mohana Rao, Madhan Mohan Reddy Products Formulation, Active Pharmaceutical Ingredient, Organic Intermediates Stock price AUROPHARMA (NSE) ₹ 666.95 -11.30 (-1.67%)2 Mar, 3:47 PM IST - Disclaimer Founders K. Nityananda Reddy, P.V. Ramprasad Reddy | ||
Aurobindo pharma corporate film
Aurobindo Pharma Limited is a pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s area of activity includes six major therapeutic/product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer.
Contents
Company
The company commenced operations in 1988-89 with a single unit manufacturing semi-synthetic penicillin (SSP) in Puducherry. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. Aurobindo Pharma also has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.
Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues. Aurobindo exports to over 125 countries across the globe with more than 70% of its revenues derived out of international operations.
In 2014, Aurobindo purchased the generic operations of Actavis in 7 Western European countries for $41 million.
Legal issues
In December 2016, the attorneys general of 20 states filed a civil complaint accusing Aurobindo Pharma of a coordinated scheme to artificially maintain high prices for a generic antibiotic and diabetes drug. The complaint alleged price collusion schemes between six pharmaceutical firms including informal gatherings, telephone calls, and text messages.